Enobosarm
From WikiMD's Food, Medicine & Wellness Encyclopedia
What is Enobosarm?[edit | edit source]
- Enobosarm, also known by its developmental code name GTx-024 and trade name Ostarine, is a selective androgen receptor modulator (SARM) that has gained attention for its potential therapeutic applications in muscle wasting conditions, osteoporosis, and other disorders.
Mechanism of Action[edit | edit source]
- Enobosarm functions by selectively binding to androgen receptors in tissues such as muscles and bones.
- Unlike traditional anabolic steroids, which can have a broad impact on various tissues including the prostate and liver, enobosarm's selective nature means it primarily targets androgen receptors in specific areas.
- Upon binding to these receptors, enobosarm modulates gene expression, promoting anabolic effects in muscle tissue and bone.
- This makes it a potential therapeutic agent for conditions involving muscle wasting, bone density loss, and frailty.
Medical Uses[edit | edit source]
- Enobosarm has been investigated for several potential medical uses:
1. Muscle Wasting[edit | edit source]
- Enobosarm has shown promise in preventing and treating muscle wasting conditions, including those related to cancer, chronic obstructive pulmonary disease (COPD), and other chronic illnesses.
- By promoting muscle growth and preventing muscle loss, it may improve patients' quality of life and overall physical function.
2. Osteoporosis[edit | edit source]
- Research suggests that enobosarm may have a positive impact on bone health by increasing bone mineral density and reducing the risk of fractures.
- This potential makes it an intriguing option for osteoporosis treatment and prevention.
3. Hormone Replacement Therapy[edit | edit source]
- Enobosarm's selective androgen receptor modulation could potentially provide an alternative to traditional hormone replacement therapies for individuals with androgen deficiencies.
Clinical Trials[edit | edit source]
- Enobosarm has been studied extensively in clinical trials to assess its safety, efficacy, and potential benefits.
- Research has focused on various patient populations, including those with muscle wasting disorders and osteoporosis.
- Many trials have reported positive outcomes related to muscle mass, physical function, and bone health.
- However, it's important to note that enobosarm is still being researched, and further studies are needed to fully establish its safety profile and long-term effects.
Side Effects[edit | edit source]
- Enobosarm has generally shown a favorable safety profile in clinical trials.
- Reported side effects have been mild and include headache, back pain, and nausea.
- Additionally, because enobosarm is a SARM and not a traditional anabolic steroid, it may have a reduced risk of causing hormonal imbalances and related side effects.
Regulatory Status[edit | edit source]
- Enobosarm has not received full regulatory approval in many countries as of the current date.
- It is important to recognize that its development and regulatory status may vary by region.
- Some countries may permit its use in clinical trials, while others may not have approved it for any use.
Conclusion[edit | edit source]
- Enobosarm, as a selective androgen receptor modulator, holds promise for addressing muscle wasting, osteoporosis, and potentially other conditions.
- Its selective binding to androgen receptors offers the potential for therapeutic benefits with fewer side effects compared to traditional anabolic steroids.
- While research is ongoing and regulatory approvals are pending in some regions, enobosarm's potential applications in improving muscle health and bone density are of significant interest to the medical community.
- Continued research will provide a clearer understanding of its benefits and safety profile.
References[edit | edit source]
- Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-61. doi: 10.1007/s13539-011-0034-6. PMID: 22031847; PMCID: PMC3177038.
- Cilotti A, Falchetti A, Banti C, et al. Ostarine (GTx-024, MK-2866): a Selective Androgen Receptor Modulator (SARM) for treatment of muscle-wasting related to cancer, osteoporosis and aging. Report on the consensus meeting. Rome, 8-9 October 2015. J Endocrinol Invest. 2016 Feb;39(2):117-22. doi: 10.1007/s40618-015-0352-y. Epub 2016 Jan 8. PMID: 26738792.
Enobosarm Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen